BC3195

DRUG2 trials

Sponsors

Biocity Biopharmaceutics Co., Ltd.

Conditions

Advanced CancerLocally Advanced or Metastatic Solid TumorsMetastatic Solid Tumor

Phase 1

A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer

RecruitingNCT06548672

Biocity Biopharmaceutics Co., Ltd.Advanced Cancer, Metastatic Solid Tumor

Start: 2024-06-24End: 2027-06-30Target: 148Updated: 2024-08-12

BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

RecruitingNCT07469774

Biocity Biopharmaceutics Co., Ltd.Locally Advanced or Metastatic Solid Tumors

Start: 2026-03-31End: 2028-12-31Target: 111Updated: 2026-05-28

Related Papers

BC3195, a novel ADC targeting cadherin-3 (CDH3): Preliminary results of a phase I study in patients with advanced solid malignancies (study BC3195-102).

Journal of Clinical Oncology2026-05-27